Platform

Engineered cell chassis for synthetic biology programs

Pre-characterized host strains, rigorous expression profiling, and documented technical transfer — built for founding teams who need validated infrastructure fast.

Cell chassis is infrastructure, not science — yet every early-stage biotech rebuilds it from scratch

The founding-team cell-line trap

Biotech startups and academic spinouts developing novel therapeutics, commodity chemicals, or specialty enzymes via microbial or mammalian cell fermentation face a problem that is as predictable as it is costly: before any differentiated science can run, someone has to build the production infrastructure.

Engineering a robust production cell line from scratch consumes 12-18 months of scientist time and strains constrained early-stage lab budgets. That is time and capital spent on work that does not differentiate your program — on rounds of cloning, passage screening, and documentation that every biotech before you has already done in isolation, without sharing the results.

The cell chassis build delays partner programs, burns runway before any differentiated data exists, and can miss funding milestones that depend on having validated production infrastructure. For a 2-15 FTE team with $500K-$5M in initial capital, the cost of rebuilding from scratch is not just financial. It is a strategic delay that compounds at every subsequent stage.

12-18 mo Time to first stable cell line when building from scratch
40-60% Of early-stage R&D budget consumed before differentiated work starts
6-8 Average cloning and characterization rounds for a de novo mammalian chassis

From sequence submission to validated working-cell bank

You provide the science context. Chassiscell delivers the infrastructure — on a timeline designed to hit your next funding milestone.

Input

What you provide

Target gene sequence (FASTA + codon-usage table), expression titer goals, regulatory context (GMP or research grade), and preferred host organism class — E. coli, CHO, yeast, or Bacillus.

Processing

What we do

Our scientists select from a library of pre-characterized chassis variants, tune promoter and codon-optimization configurations, perform an accelerated stability and productivity screen across three passage cycles, and deliver a validated working-cell bank with full documentation.

Output

What you receive

Validated working-cell bank, expression characterization report, plasmid map and sequence files, stability data across 30 generations, and a technical transfer dossier ready for in-house scale-up or CMO handoff.

Integration-ready deliverables

  • CMO / CDMO process development handoff — cell-bank with full characterization dossier formatted for Lonza, WuXi Biologics, and Thermo Fisher CTS transfer requirements
  • Partner internal sequence design tools — accepts FASTA + codon-usage table inputs; compatible with Benchling plasmid registry
  • ELN / LIMS via CSV export — compatible with LabArchives, Dotmatics, and Sapio
  • GMP documentation systems — audit-ready IND-stage records on request, aligned with FDA and EMA common technical document expectations

Six integrated capabilities for rigorous cell chassis delivery

Each capability is designed to replace a specific bottleneck in the traditional in-house cell-line development workflow.

Pre-characterized chassis library — sequence-verified strain vials in organized cold storage
Library

Pre-Characterized Chassis Library

50+ IP-cleared host strains pre-screened for metabolic stability, growth kinetics, and regulatory safety

Our chassis library spans six host organism classes — E. coli BL21 derivatives, CHO-K1 sub-clones, S. cerevisiae BY strains, P. pastoris X-33, B. subtilis 168, and two proprietary low-endotoxin E. coli variants. Each strain is fully sequence-verified, passaged under defined conditions, and annotated with plasmid compatibility, induction window, and typical titer range for common payload categories. Partners skip the 6-8 cloning rounds needed to develop a chassis from scratch and start expression optimization from a known baseline.

Rapid expression profiling — 96-well microfermentation plate setup in progress
Profiling

Rapid Expression Profiling

Parallel screening of 8 promoter-codon combinations in under 4 weeks

Expression profiling runs eight combinations of promoter strength, codon optimization profile, and signal peptide variant in parallel 96-well microfermentation, quantifying soluble yield, aggregation index, and post-translational modification profile. The four highest-performing constructs advance to bench-scale shake-flask validation in week three. Partners receive ranked constructs with accompanying analytics and the reasoning behind our recommended selection, enabling an informed go/no-go before committing to a full development run.

Stability screen — sequential passage cycle records organized at a lab bench
Stability

Stability and Productivity Screen

30-generation passage screen confirms expression consistency before partner hand-off

Genetic stability is validated through three sequential passage cycles — 10 generations each — with titer, viability, and plasmid retention measured at each checkpoint. Productivity drift greater than 15% triggers an automated flag and a root-cause analysis before the cell bank is released. The resulting stability dataset gives partners and downstream CMOs the data package required for IND-enabling studies and reduces the risk of clonal instability surfacing late in development when correction costs are highest.

Technical transfer dossier — formatted documentation stack ready for CMO handoff
Documentation

Documented Technical Transfer

Full sequence-to-bank documentation package ready for CMO handoff or IND filing

Every cell bank includes a standardized technical transfer dossier: plasmid sequence and annotated map, codon-optimization rationale, host selection rationale, induction protocol, recommended media formulation, raw and summary stability data, and a certificate of analysis. The dossier is formatted to align with FDA and EMA common technical document expectations, minimizing the document-preparation burden partners face when transitioning from research to regulated manufacturing contexts.

Custom chassis engineering — molecular biology bench with edited pathway constructs
Custom Build

Custom Chassis Engineering

De novo chassis construction for partners with unusual host or pathway requirements

When no library chassis matches the partner's biosynthesis pathway, toxin tolerance requirement, or preferred fermentation format, Chassiscell's science team undertakes targeted engineering: deletion of competitive metabolic sinks, insertion of auxiliary pathway genes, or co-optimization of membrane composition to accommodate hydrophobic product export. Custom chassis projects follow a defined three-milestone structure — design review, prototype validation, and final bank release — with clear go/no-go criteria at each gate and fixed-fee pricing per milestone.

Partner program coordination — scientists reviewing progress against milestone schedule
Coordination

Partner Program Coordination

Dedicated program manager and shared project workspace for real-time visibility

Each partnership is assigned a dedicated program manager who serves as the primary scientific contact throughout the engagement. Partners receive weekly written updates, access to a shared project workspace with live milestone tracking, and an open-channel protocol for ad hoc troubleshooting questions. This coordination layer reduces the back-and-forth latency that typically slows cell-line projects when key decisions wait on email threads, and ensures that timeline risks surface early enough to be addressed without schedule impact.

Built for founding teams with differentiated science and constrained timelines

Primary Segment

Pre-seed to seed-stage biotech startups and academic spinouts entering their first microbial or mammalian cell production program. Typically 2-15 FTE science teams with $500K-$5M in initial capital, needing validated cell chassis within 3-6 months to hit their next funding milestone.

What We Replace

The 12-18 month in-house chassis build: the cloning rounds, the passage screening campaigns, the undocumented institutional knowledge that only lives in one scientist's notebook. We replace that with a validated, IP-cleared starting point and a documentation package that survives personnel changes and due diligence.

Timeline Fit

Our library selection + expression profiling + stability screen + bank production sequence is designed to run in 10-16 weeks — compressed to fit the pre-seed to seed fundraising cycle where validated production infrastructure is a tangible milestone, not a future promise.

Not For

Large pharma or established CDMOs with in-house cell-line development capacity, or programs requiring full GMP manufacturing rather than research-grade cell-bank delivery. If your team already has a functioning, characterized chassis and a full-time cell biologist, you probably do not need us yet.

Tell us your sequence and goals

We will confirm library fit within five business days and outline a project timeline aligned with your funding milestones.

Request a Partner Conversation